CAR-T cell therapy: DCGI approves NexCAR19 for blood cancer treatment

Immunoadoptive Cell Therapy Private Limited (“ImmunoACT”) has received the marketing authorization approval for the first humanized CD19-targeted Chimeric Antigen Receptor T cell (CAR-T cell) therapy product for relapsed / refractory (r/r) B-cell lymphomas and leukemia in India.

NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy. It is the first-of-its kind, a Made-in-India product.

The multi-center Phase I/ II pivotal clinical trial, led by Dr Hasmukh Jain, was conducted with 60 patients of r/r B-cell lymphomas and leukemia. The clinical data indicates ~70% overall response rate (ORR). The safety profile in terms of cytokine release syndrome (CRS) and absence of neurotoxicity indicates a significant improvement over the other commercially approved CD19-directed CAR-T cell therapies.

For more details, check out the link given below:

Breakthrough Made-In-India CAR-T Cell Therapy NexCAR19 Gets DCGI Nod For Blood Cancer Treatment